Cathepsin L1 – Pipeline Review, H1 2020

Cathepsin L1 – Pipeline Review, H1 2020



Summary



Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) – Cathepsin L, a lysosomal endopeptidase is a member of the papain-like family of cysteine proteinases. Cathepsin L plays a major role in antigen processing, tumor invasion and metastasis, bone resorption, and turnover of intracellular and secreted proteins involved in growth regulation. Although commonly recognized as a lysosomal protease, cathepsin L is also secreted. The cathepsin L gene is activated by a variety of growth factors, tumor promoters, and second messengers. Cathepsin L promote tumor cell invasion and metastasis by catalyzing degradation of the interstitial matrix and basement membranes, thus allowing cancer cells to invade locally and metastasize to distant sites.



Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) pipeline Target constitutes close to 7 molecules. The molecules developed by companies in Phase 0, Preclinical and Discovery stages are 1, 3 and 3 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Infectious Disease, Gastrointestinal and Immunology which include indications Autoimmune Disorders, Breast Cancer, Cancer Pain, Coronavirus Disease 2019 (COVID-19), Head And Neck Cancer Squamous Cell Carcinoma, Liver Fibrosis, Metastatic Prostate Cancer, Middle East Respiratory Syndrome (MERS), Neuropathic Pain (Neuralgia), Osteosarcoma, Pancreatic Cancer, Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and Severe Acute Respiratory Syndrome (SARS).



The latest report Cathepsin L1 – Pipeline Review, H1 2020, outlays comprehensive information on the Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics development with respective active and dormant or discontinued projects.



The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.



Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.



Scope



– The report provides a snapshot of the global therapeutic landscape for Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)

– The report reviews Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics and enlists all their major and minor projects

– The report assesses Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics



Reasons to Buy



– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand the targeted therapy areas and indications for Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)

– Identify the use of drugs for target identification and drug repurposing

– Identify potential new clients or partners in the target demographic

– Develop strategic initiatives by understanding the focus areas of leading companies

– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

– Devise corrective measures for pipeline projects by understanding Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) development landscape

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Companies Mentioned:

Mateon Therapeutics Inc

Phelix Therapeutics LLC

Vanda Pharmaceuticals Inc

Virobay Inc

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: enquiry@researchbymarkets.com *Industry Press Release is a part of Research By Markets.